ZVRA logo

ZVRA
Zevra Therapeutics Inc

24,195
Mkt Cap
$563.04M
Volume
671,550.00
52W High
$13.16
52W Low
$6.52
PE Ratio
6.50
ZVRA Fundamentals
Price
$9.71
Prev Close
$9.59
Open
$9.50
50D MA
$9.17
Beta
0.82
Avg. Volume
1.49M
EPS (Annual)
$1.35
P/B
3.57
Rev/Employee
$1.75M
$385.27
Loading...
Loading...
News
all
press releases
Stratos Wealth Partners LTD. Boosts Stake in Zevra Therapeutics, Inc. $ZVRA
Stratos Wealth Partners LTD. increased its position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 78.6% in the 4th quarter, according to its most recent filing with the SEC. The fund...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
JPMorgan Chase & Co. Has $4.18 Million Stock Holdings in Zevra Therapeutics, Inc. $ZVRA
JPMorgan Chase & Co. lifted its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 1,458.8% in the third quarter, according to its most recent filing with the SEC. The firm...
MarketBeat·6d ago
News Placeholder
Hennion & Walsh Asset Management Inc. Invests $1.25 Million in Zevra Therapeutics, Inc. $ZVRA
Hennion & Walsh Asset Management Inc. acquired a new stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 139,591 shares of the company's sto...
MarketBeat·7d ago
News Placeholder
John B Bode At Zevra Therapeutics Executes Options Exercise, Realizing $326K
read more...
Benzinga·14d ago
News Placeholder
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Moderate Buy" by Analysts
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the firm, MarketBeat Ratings...
MarketBeat·19d ago
News Placeholder
Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap Up - Still a Buy?
Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap Up - Here's What Happened...
MarketBeat·24d ago
News Placeholder
Zevra Therapeutics (NASDAQ:ZVRA) Now Covered by BTIG Research
BTIG Research began coverage on shares of Zevra Therapeutics in a research note on Monday. They issued a "buy" rating and a $23.00 target price on the stock...
MarketBeat·25d ago
News Placeholder
Zevra Therapeutics, Inc. $ZVRA Shares Bought by Kingdon Capital Management L.L.C.
Kingdon Capital Management L.L.C. lifted its holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 44.4% in the 3rd quarter, according to the company in its most recent disclosure with...
MarketBeat·25d ago
News Placeholder
Zevra Therapeutics (NASDAQ:ZVRA) Cut to "Hold" at Wall Street Zen
Wall Street Zen lowered Zevra Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday...
MarketBeat·27d ago
News Placeholder
Analysts Set Expectations for ZVRA Q1 Earnings
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research note...
MarketBeat·29d ago
<
1
2
...
>

Latest ZVRA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.